Advanced in Hepatocerebral Degeneration

Antonio Olveira

Madrid, MD, ES 
Advanced in Hepatocerebral Degeneration
Madrid, MD, ES 
OverviewLocationsClinical Research

Overview

Antonio Olveira practices in Madrid, Spain. Mr. Olveira is rated as an Advanced expert by MediFind in the treatment of Hepatocerebral Degeneration. His top areas of expertise are Hepatitis C, Cirrhosis, Hepatitis, and Non-Alcoholic Fatty Liver Disease.

His clinical research consists of co-authoring 63 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Hepatocerebral Degeneration.

Gender
Male

Locations

Madrid, MD, Spain
Other Locations
La Paz, MD, Spain
La Paz, CN, Spain
Castellana, MD 28046, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm
A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, Open Label, Multicentric Clinical Trial of a Single Arm of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotype 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A
A Phase III, Open Label, Multicentric Clinical Trial of a Single Arm of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotype 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A
Enrollment Status: Withdrawn
Publish Date: June 08, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 2 Less Clinical Trials

63 Total Publications

Reconnecting hepatitis C patients lost to follow-up ‒A targeted strategy.
Reconnecting hepatitis C patients lost to follow-up ‒A targeted strategy.
Journal: Revista espanola de enfermedades digestivas
Published: September 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Olveira's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile